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Malignant mesothelioma (MM) is a rare form of cancer. Its histo-
pathological diagnosis is very difﬁcult, as it exhibits a number of
different appearances that can be misinterpreted as metastatic
invasion or atypical hyperplasia. Thus, there is an urgent need to
identify adequate markers to distinguish between benign and ma-
lignant cells, allowing the implementation of appropriate therapies
and, possibly, speciﬁc directed therapies. MM, like other tumors,
show an increase in glucose uptake, due to high rates of glycolysis,
inducing an intracellular overload of acids. In this context, mono-
carboxylate transporters (MCTs) emerge as important players, by
mediating the transmembranar co-transport of lactate with a pro-
ton, thereby, regulating pH and allowing continuous glycolysis.
Importantly, proper MCT expression and activity depend on its co-
expression with a chaperone, CD147, which is associated with
poor prognosis in cancer. Twenty-two samples including reactive
mesothelial cells, MM, and atypical mesothelial hyperplasias were
evaluated for immunoexpression of MCT1, MCT4, and CD147.
Expression of these proteins was compared with GLUT1 as a new
promising marker for MM. Although MCT isoforms were not differ-
entially expressed in the two types of cytological specimens,
CD147, as GLUT1, was almost exclusively expressed in MM. Both
MCT1 and MCT4 are not able to discriminate between mesothelial
reactive cells and mesothelial malignant cells, while CD147 was
able to distinguish these two proliferations. If conﬁrmed, besides
being a good marker for identiﬁcation of MM, CD147 may also be
a target for therapeutical strategies in this rare type of tumor.
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Malignant mesothelioma (MM), a neoplasm of mesothe-
lial cells from the serosal membranes occurs predomi-
nantly in the pleura, less often in the peritoneum, seldom
in pericardium, and rarely in the tunica vaginalis testis.
Asbestos exposure is the most common cause of MM and
its connection with this rare form of cancer has been well
established for the last half a century.1 The long-latency
period from initial asbestos exposure to development of
MM is responsible for an incidence of nearly 3,000 new
cases a year in the U.S., a number that may remain at
that level for the foreseeable future.2 The number of MM
diagnosed worldwide may also grow larger due to pathol-
ogists’ increasing ability in recognizing MM and to the
emergence of newer immunohistochemical markers with
restrictive speciﬁcity for this neoplasm.
Current MM treatment is complex and the results are
far from ideal. Surgery cannot remove all the residual mi-
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croscopic cancer deposits and as a result, surgical treat-
ment for operable MM even in able hands cannot be con-
sidered a deﬁnite form of therapy.3 Even with new forms
of systemic therapy, survival beyond 12–18 months is
extremely rare.4 Attempts at combined chemotherapy,5
gene therapy,6 and immunotherapy with vaccines7 have
not fared any better. The attention, therefore, has shifted
to targeted therapy directed at molecular events involved
in the survival and growth of malignant transformed me-
sothelial cells. Speciﬁc-targeted therapy has been a suc-
cess story in the treatment of GIST and other tumors and
constitutes a promising option for the treatment of MM.8
A precise pathological diagnosis of MM remains cru-
cial for instituting appropriate therapeutic intervention.
Early diagnosis offers the best opportunity for successful
outcomes in any treatment strategy and cytological exami-
nation of effusion specimens offers the greatest chance
for achieving it. However, in its early stage, the distinc-
tion between MM and atypical mesothelial hyperplasia
still represents a very difﬁcult challenge.9 Cytological
results have vastly improved with the use of newer anti-
body panels but no infallible marker has been developed
to distinguish reactive mesothelial hyperplasia from
MM.10,11 More recently, the combination of positive epi-
thelial membrane antigen (EMA) and negative desmin
was interpreted to strongly favor MM, whereas a combi-
nation of negative EMA and positive desmin favors a re-
active process.12
Some new promising markers have emerged recently,
including GLUT1,13 which play a role in cellular glyco-
lytic metabolism. The expression of GLUT1 may even
discriminate between reactive mesothelium and MM,13
although with a lower speciﬁcity and sensitivity than orig-
inally claimed.14 Following this line of evidence, some
studies suggest that positron emission tomography with
18F-ﬂuorodeoxyglucose (FDG-PET) imaging could be an
effective tool for differentiating between benign and ma-
lignant pleural diseases,15–17 indicating a higher glycolytic
metabolism in the malignant context. It is widely known
that, under hypoxic conditions, cancer cells obtain energy
by increasing their rates of glycolysis leading to an over-
load of intracellular lactic acid, which must be transported
out of the cell, a process that results in extracellular acidi-
ﬁcation. Low interstitial pH is associated with the upregu-
lation of various angiogenic molecules such as VEGF, IL-
8, bFGGF, and Heparanase, all of which may provide
autocrine stimulation and contribute to tumor aggressive-
ness.18 Cancer lactate accumulation has also been corre-
lated with poor clinical outcomes,19–21 a property that
remains yet to be explored as part of tumoral treatment
strategies. One of the most important players in this con-
text is monocarboxylate transporters (MCTs), which are
also responsible for transmembrane co-transport of lactate
with a proton, thus regulating pH and enabling continuous
glycolysis. The authors have observed that some MCT
isoforms (MCT1 and MCT4) and their chaperone CD147
are overexpressed in a variety of solid tumors, including
cervical carcinoma,22,23 colorectal carcinoma,24 and basal-
like carcinoma of the breast25 but not in gastric carci-
noma.26 Since MCT activity supports cancer cell survival,
their capacity to transport lactate can be explored as a
new therapeutic target. In addition, CD147, the MCT1/
MCT4 chaperone, was shown to contribute to tumoral
progression and metastasis. Therefore, the metabolic mod-
iﬁcation of tumor’s microenvironment mediated by
MCT1/CD147 holds promise as a target for future thera-
peutic options.27 Despite their potential as molecular ther-
apeutic targets for neoplasms relying on glycolytic metab-
olism, MCTs have not been investigated in MM. The aim
of this study was to characterize the expression of mono-
carboxylate transporters 1 and 4 and their chaperone
CD147 in benign and malignant mesothelial cells, and
compare their expression with GLUT1, a new promising
MM marker.
Material and Methods
Samples were obtained from 20 patients including 11 me-
sothelial reactive cells and 9 MM. Samples were retrieved
from the consultation ﬁles of one of the authors (CWB).
Relevant data available included patient’s age and gender,
source of the effusion as well as the ﬁnal histopathologi-
cal diagnosis in pleural biopsies or decortication speci-
mens.
Immunohistochemistry
MCT, CD147, and GLUT1 detection. MCT immunohis-
tochemistry was performed according to the avidin–bio-
tin–peroxidase complex method (R.T.U. VECTASTAIN
Elite ABC Kit (Universal), Vector Laboratories, Burlin-
game, CA), with primary antibodies for MCT1
(AB3538P, Chemicon International, Temecula, CA), and
MCT4 (AB3316P, Chemicon International, Temecula,
CA), diluted 1:200, as previously described.24 Immunohis-
tochemistry for CD147 and GLUT1 was performed
according to the streptavidin–biotin–peroxidase complex
principle Ultravision Detection System Anti-polyvalent,
HRP, Lab Vision Corporation, Fremont, CA), using pri-
mary antibodies raised against CD147 (18-7344, ZYMED
Laboratories Inc., South San Francisco, CA, diluted
1:750, as previously described23) and GLUT1 (ab15309,
AbCam, Cambridge, UK, diluted 1:500, same protocol as
for CD147). Negative controls were performed using
appropriate serum controls for the primary antibodies
(N1699, Dako, Carpinteria, CA), colon carcinoma tissue
was used as positive control for both MCT1 and MCT4,
cervical squamous carcinoma for CD147 and skin for
GLUT1. Tissue sections were counterstained with hema-
toxylin and permanently mounted.
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Immunohistochemical evaluation. Sections were scored
semi-quantitatively for immunoreaction as follows: 0: 0%
of immunoreactive cells; 1: <5% of immunoreactive
cells; 2: 5–50% of immunoreactive cells; and 3: >50% of
immunoreactive cells. Also, intensity of staining was
scored semi-qualitatively as follows: 0: negative; 1: weak;
2: intermediate; and 3: strong. The ﬁnal score was deﬁned
as the sum of both parameters (extent and intensity), and
grouped as negative (score 0 and 2) and positive (score
3–6), as previously described.24 Since plasma membrane
location of these proteins is essential for activity, when
present, the signiﬁcance of plasma membrane positivity
for MCTs, CD147, and GLUT1 was evaluated separately.
Immunohistochemical evaluation was performed blindly
by two independent observers and discordant cases were
discussed using a double-head microscope to determine
the ﬁnal score.
Statistical Analysis
Data were stored and analyzed using the SPSS statistical
software (version 16.0, SPSS, Chicago, IL). All compari-
sons were examined for statistical signiﬁcance using Pear-
son’s chi-square (v2) test and Fisher’s exact test (when
n < 5), being threshold for signiﬁcance P values <0.05.
Results
Twenty samples from 16 male and 4 female patients were
assessed for MCT1, MCT4, CD147, and GLUT1 immu-
nohistochemical expression. The results obtained for each
case are summarized in Table I. Positive MCT1 expres-
sion was observed in both plasma membrane and cyto-
plasm (Figs. 1A and 1E), while MCT4 was only found in
the cytoplasm (Figs. 1B and 1F). Regarding CD147,
except for one case, expression was always present in the
plasma membrane (Fig. 1G), with some cytoplasmic stain-
ing. GLUT1 expression was present in the plasma mem-
brane of all positive cases (Fig. 1H), showing also a
strong plasma membrane expression in red blood cells
(Fig. 1D).
Comparison between the expression frequencies of all
markers in MM cells and mesothelial reactive cells is
depicted in Table II. No statistically signiﬁcant difference
was observed between the benign and malignant samples
with regards to their MCT1 and MCT4 expression. In
contrast, the expression of CD147 was signiﬁcantly
increased in the MM samples, being expressed in about
90% (8/9) of MM vs. 9% (1/11) for mesothelial reactive
cells (P ¼ 0.001). The power of CD147 to distinguish be-
nign from malignant mesothelial cells was the same as
that of GLUT1, with about 90% of positivity for MM vs.
9% for mesothelial reactive cells (P ¼ 0.001), corre-
sponding to a sensitivity of 88.8% and speciﬁcity of
90.9%. No associations were found between either of the
two MCTs, CD147, or GLUT1 and age or gender (data
not shown). In addition, MCTs were not signiﬁcantly
co-expressed with CD147 (data not shown).
Discussion
Appropriate therapeutic intervention in MM can only be
achieved if an accurate pathological diagnosis is made.
However, the distinction between MM and atypical meso-
thelial hyperplasia at early stages remains very difﬁcult.9
Therefore, there is an urgent need to establish efﬁcient
markers to distinguish between these two cytological
entities.
Table I. Immunohistochemical Characterization of MCT1, MCT4, CD147, and GLUT1 in 20 Patients with Mesothelioma and Benign Mesothelial
Reaction
Case Gender Age
Histopathological
diagnosis
MCT1
score
MCT1
membrane
MCT4
score
CD147
score
CD147
membrane
GLUT1
membrane
1 Male 82 Mesothelioma + + + + + +
2 Male 70 Benign + + +   
3 Male 80 Mesothelioma + +  + + +
4 Male 47 Benign   +   
5 Male 69 Mesothelioma + + + + + +
6 Male 78 Mesothelioma + + + + + +
7 Female 78 Benign + + +   
8 Male 82 Benign + +  n.a. n.a. 
9 Male 81 Mesothelioma + +  + + +
10 Male 81 Benign + + + + + 
11 Male 58 Benign   +   
12 Female 72 Mesothelioma + + + + + +
13 Male 69 Benign + +    
14 Male 76 Benign + +    
15 Female 52 Benign +   +  
16 Male 62 Benign + + +   
17 Male 89 Benign + + +   +
18 Male 55 Mesothelioma + + + + + +
19 Female 73 Mesothelioma + + +   +
20 Male 55 Mesothelioma + +  + + 
Benign means hyperplastic reactive mesothelia.n.a., not available.
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To the best of our knowledge, the results in this study
describe for the ﬁrst time the expression of monocarboxy-
late transporters 1 and 4 in MM. However, neither MCT1
nor MCT4 showed any signiﬁcant discriminating value in
the recognition of malignancy. Actually, the values
observed show a very similar pattern between mesothe-
lial-derived malignancy and benign cells. Of note, MCT4
positive reaction was predominantly found in the cyto-
plasm which can explain, in part, the lack of signiﬁcance
of MCT4 in MM. Conversely, despite detection of MCT1
within the plasma membrane, MCT1 reaction did not
show signiﬁcant differences either. The overexpression of
monocarboxylate transporters in both reactive mesothe-
lium and MM supports the intriguing notion that benign
mesothelial proliferations may be a precursor lesion of
MM. In fact, the evolution of atypical mesothelial hyper-
plasia to invasive peritoneal MM has been documented, 8
years from the original non-MM diagnosis.28 Unfortu-
nately, no laparoscopy or biopsy was available in the
intervening years, to document or dispel the presence of
an in situ stage.
CD147, also known as extracellular matrix metallopro-
teinase inducer (EMMPRIN), is recognized to promote tu-
mor angiogenesis mostly through its protease-inducing
function. Remarkably, the plasma membrane expression
of CD147 was associated with MM, since the majority of
MM cases were positive for CD147 and only 1 case of
mesothelial hyperplasia was decorated by CD147 immu-
noreaction. This fact may be important on two different
bases: ﬁrst, membranous positive reaction for CD147
revealed to be a reliable marker of MM; second, it could
be considered as a promising candidate for speciﬁc-tar-
geted therapy. A more recent study revealed that CD147
may directly contribute to the angiogenic process regula-
tion by association with upregulation of HIF-2a, VEGFR-
2, and the soluble forms of VEGF in endothelial cells.29
This ﬁnding corroborated, in part, our previous report,
where we found that VEGFR-3, a lymphatic vessel recep-
tor which may be highly expressed in tumor cells and
blood vessels of certain malignancies, was overexpressed
in MM.30 Importantly, these results also suggest that, in
addition to increasing protease production, CD147 may
contribute to the upregulation of soluble forms of VEGF
in endothelial cells, thus directly regulating the angiogenic
process. However, CD147 was not found to be accurate
in predicting MM aggressiveness.31
MM responds unpredictably to therapy and treatment
results seem to be related to biological properties, rather
than to cytological grading or clinical staging. Molecular
markers provide evergrowing insight into the biology of
MM, but fall short of being prognostic factors or as gages
Fig. 1. Immunohistochemical expression of monocarboxylate transporter 1 (MCT1), MCT4, CD147, and glucose transporter 1 (GLUT1) in mesothelial
samples. (A) MCT1 in benign mesothelial cells; (B) MCT4 in benign mesothelial cells; (C) CD147 in benign mesothelial cells; (D) GLUT1 in benign
mesothelial cells; (E) MCT1 in malignant mesothelial cells; (F) MCT4 in malignant mesothelial cells; (G) CD147 in malignant mesothelial cells; (H)
GLUT1 in malignant mesothelial cells. Note the strong expression of GLUT1 in the plasma membrane of red blood cells (D). [Color ﬁgure can be
viewed in the online issue, which is available at wileyonlinelibrary.com.]
Table II. Frequency of MCT1, MCT4, CD147, and GLUT1
Expressions in Mesothelioma Compared to Mesothelial Reactive Cells
n Positive (%) P
MCT1 (membrane) 0.218
Mesothelial reactive cells 11 8 (72.7)
Mesothelioma 9 9 (100.0)
MCT4 (cytoplasm) 1.000
Mesothelial reactive cells 11 7 (63.6)
Mesothelioma 9 7 (66.7)
CD147 (membrane) 0.001
Mesothelial reactive cells 11 1 (9.1)
Mesothelioma 9 8 (88.9)
GLUT1 (membrane) 0.001
Mesothelial reactive cells 11 1 (9.1)
Mesothelioma 9 8 (88.9)
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of treatment response. Currently, GLUT1 appears promis-
ing for guiding therapeutic strategies and evaluating their
effectiveness. The strong GLUT1 expression the authors
observed in MM conﬁrms the experience of other investi-
gators and suggests that MM has a preference for glycoly-
sis.13 This property has been utilized in positron emission
tomography (PET) in the evaluation of response to ther-
apy.32 Based on these prior observations one would
expect that either MCT1 or MCT4 would be upregulated
in MM, but this was not the case in our study. In fact,
both MCT1 and MCT4 were equally positive in MM and
mesothelial hyperplasia suggesting that these molecules
behave as other proliferative markers that are positive in
these two settings but cannot discriminate between them.
On the other hand, the immunopositivity for CD147 paral-
leled the results of GLUT1, supporting the notion that
CD147 is a valuable discriminator between benign and
malignant mesothelial proliferations. In addition, we
found that CD147 positive reactions were easier to inter-
pret, since this marker did not stain red blood cells, as is
the case with GLUT1 in the study of bloody effusions.
Just as hyperthermic intraperitoneal chemotherapy enhan-
ces the results of cytoreductive surgery,33 it seems plausi-
ble to assume that altering the pH in the microenviron-
ment of MM may enhance other modalities of therapy.
This possibility has not been investigated.
In this study, although MCT expression was not
increased in MM, when compared with reactive mesothe-
lial cells, CD147 was found to discriminate between these
two cytological entities, in a similar method to that
described for GLUT1. However, our current ﬁndings
deserve further study to substantiate their validity and to
explore the potential use of CD147 as a factor in novel
treatment strategies.
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